Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
Form 4 filing overview: BeOne Medicines Ltd. (ticker ONC) President & COO Xiaobin Wu reported three sales of the company’s American Depositary Shares (ADS) on 16-17 Jun 2025. Each ADS represents 13 ordinary shares.
- Shares sold: 2,173 ADS in total (1,443 ADS at $265.4695 weighted average, 100 ADS at $266.22, and 630 ADS at $250.8686).
- Proceeds: ≈ $555 thousand based on the disclosed prices.
- Reason: All sales were automatically executed under the mandatory tax-withholding feature of the executive’s Restricted Share Unit (RSU) agreements, coinciding with scheduled vesting dates.
- Residual ownership: After the transactions Wu still directly owns 1,246,047 ordinary shares and 0 ADS; indirectly, his spouse controls 4,000 ADS.
- Vesting schedule: The underlying RSUs vest 25 % annually from either 15 Jun 2023 or 16 Jun 2021, with accelerated vesting on certain termination events.
Investor take-away: The disposition represents <1 % of the executive’s economic exposure to ONC and was not discretionary trading. Accordingly, the filing is viewed as routine compliance rather than a signal of changing insider sentiment.
Form 4 Overview – BeOne Medicines Ltd. (ONC)
Chief Executive Officer and Director John Oyler filed a Form 4 covering two transactions executed on 16-17 June 2025. Both involved the company’s American Depositary Shares (ADS), each representing 13 ordinary shares.
- 16 Jun 2025: 3,680 ADS sold under transaction code “S” at a weighted-average price of $266.0452.
- 17 Jun 2025: 1,460 ADS sold under transaction code “S” at a weighted-average price of $256.4885.
Total ADS disposed: 5,140, equivalent to ≈66,820 ordinary shares. Gross proceeds, based on the reported weighted averages, amount to roughly $1.35 million.
The filing notes that both sales were automatically executed to cover mandatory tax-withholding obligations tied to the vesting of previously granted restricted share units (RSUs). They were not discretionary open-market sales.
Post-transaction holdings
- Direct holdings: 8,215,021 ordinary shares and 0 ADS.
- Indirect holdings (multiple trusts and entities): approximately 46 million ordinary shares, as detailed in five footnoted ownership vehicles. Oyler disclaims beneficial ownership of several of these positions.
No derivative security activity was reported. The transactions do not change Oyler’s board or executive status and appear administrative rather than strategic. Given the small proportion of shares sold relative to his overall beneficial ownership, market impact is likely limited.